Buy Synthroid (Levothyroxine 25/50/100/125/200mcg) Online - Dominant US Brand Bioidentical Thyroid Hormone Replacement for Hypothyroidism
Synthroid (Levothyroxine 25/50/100/125/200mcg) represents the dominant US brand of thyroid hormone replacement therapy and one of the longest continuously marketed prescription medications globally — first commercialized by Flint Laboratories in 1955 and subsequently manufactured through Boots, Knoll, Abbott, and now AbbVie Pharmaceuticals. Synthroid contains bioidentical synthetic levothyroxine sodium (T4) — chemically identical to endogenous thyroid hormone naturally produced by the thyroid gland — providing physiological replacement for hypothyroidism from any cause. As direct sibling to Eltroxin (GSK levothyroxine brand from UK/India) on rxshop.md, Synthroid provides the same generic active ingredient but with distinct manufacturer heritage and importantly five available dose strengths (25, 50, 100, 125, 200 mcg) enabling precise individualized dosing without tablet splitting for elderly starting doses, standard maintenance, and higher-dose cancer suppression protocols.
Levothyroxine works as bioidentical synthetic thyroxine (T4) — chemically identical to endogenous thyroid hormone. As a prohormone, levothyroxine is peripherally converted to active triiodothyronine (T3) by 5'-deiodinase enzymes in target tissues throughout the body providing sustained thyroid hormone activity supporting normal metabolic rate, cardiovascular function, cognitive processes, body temperature regulation, and growth and development. The long ~7-day half-life allows convenient once-daily dosing while providing steady thyroid hormone levels. Steady state requires 4-6 weeks — TSH monitoring at 6-8 week intervals guides dose adjustments during titration.
Synthroid serves comprehensive thyroid replacement needs identical to other levothyroxine brands. Primary uses include primary hypothyroidism; Hashimoto's thyroiditis (autoimmune hypothyroidism); post-thyroidectomy replacement; post-radioactive iodine (RAI) treatment; congenital hypothyroidism (critical for infant brain development); central hypothyroidism; and thyroid cancer TSH suppression at higher doses. The multiple strength availability makes Synthroid particularly convenient for cancer patients requiring higher-dose suppression protocols.
Synthroid dosed 1.6 mcg/kg/day average (typically 100-150 mcg adults). Elderly/CAD start 25-50 mcg. Take on empty stomach 30-60 min before breakfast. Avoid coffee, calcium, iron within 4 hours. Monitor TSH q6-8 weeks. Sibling brands: Eltroxin (levothyroxine) and opposite indication Carbirose.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Primary Hypothyroidism: Thyroid gland failure from any cause including autoimmune surgical or radiation-induced hypothyroidism;
- Hashimoto Thyroiditis: Chronic autoimmune destruction of thyroid gland producing progressive hypothyroidism requiring lifelong replacement;
- Post Thyroidectomy Replacement: Complete replacement therapy after surgical thyroid removal for cancer or intractable hyperthyroidism;
- Post Radioactive Iodine Ablation: Replacement after RAI treatment for Graves disease or thyroid cancer when patient becomes hypothyroid;
- Congenital Hypothyroidism: Newborn screening positive infants requiring immediate replacement for critical brain development in first year of life;
- Nodular Goiter Management: Selected cases of nodular thyroid enlargement with TSH suppression to prevent growth;
- Prevention of Recurrent Nodular Goiter: Prevention after surgical treatment or in select iodine-deficient regions;
- Diffuse Euthyroid Goiter: Enlarged thyroid with normal function - selected cases benefit from TSH suppression therapy;
- Thyroid Cancer TSH Suppression: Higher doses to suppress TSH below 0.1 mIU/L preventing differentiated thyroid cancer recurrence;
- Thyroid Cancer Post Surgery: Essential replacement after thyroidectomy for cancer with individualized TSH suppression targets;
- Central Hypothyroidism: Pituitary (secondary) or hypothalamic (tertiary) hypothyroidism requiring full replacement therapy;
- Subclinical Hypothyroidism: Elevated TSH with normal T4 in selected patients with symptoms cardiovascular risk factors or elevated TPO antibodies;
- TSH Suppression Test: Diagnostic use to suppress TSH for various clinical testing scenarios and diagnostic protocols;
- Autoimmune Thyroiditis: Various autoimmune thyroid conditions producing hypothyroidism requiring replacement therapy;
- Post Graves Disease Treatment Hypothyroidism: Replacement after RAI or thyroidectomy for Graves disease when patient becomes hypothyroid;
- Myxedema Coma Emergency: Life-threatening severe hypothyroidism requiring emergency high-dose IV replacement in hospital setting;
- Hypothyroidism in Pregnancy: Critical for fetal neurological development requirements increase 20-30% during pregnancy monitored monthly;
- Pediatric Hypothyroidism: Congenital and acquired childhood hypothyroidism requiring pediatric endocrinology supervision and weight-based dosing;
- Elderly Hypothyroidism: Age-related thyroid dysfunction requiring careful low-dose initiation with cardiovascular monitoring.
- Improves Symptoms of Hypothyroidism: Comprehensive improvement of fatigue cold intolerance dry skin constipation weight gain and other hypothyroid symptoms;
- Supports Normal Metabolic Rate: Restores basal metabolic rate reversing hypothyroid-related metabolic slowdown enabling normal energy expenditure;
- Better Energy Mood and Mental Function: Restoration of normal thyroid function improves energy levels stabilizes mood and enhances cognitive function;
- Prevents Goiter: TSH suppression prevents growth of nodular goiter and recurrence after surgical treatment;
- Treats Various Forms of Hypothyroidism: Effective for primary secondary tertiary and congenital hypothyroidism from any underlying cause;
- Safe for Pregnant Women and Elderly: Excellent safety profile in special populations with appropriate dose adjustments and monitoring;
- Minimal Side Effects: Bioidentical hormone with excellent tolerability when appropriately dosed - side effects typically only from over- or under-dosing;
- Prevents and Treats Thyroid Tumor Recurrence: TSH suppression therapy prevents differentiated thyroid cancer recurrence after surgical treatment;
- Better Five Strength Precision: 25/50/100/125/200 mcg strengths enable precise individualized dosing without tablet splitting for elderly and cancer patients;
- Better Once Daily Dosing Convenience: Long half-life (~7 days) allows convenient once daily dosing improving compliance for lifelong therapy;
- Better Bioidentical Hormone: Chemically identical to endogenous thyroxine providing physiological replacement without foreign substance concerns;
- Better Peripheral T3 Conversion: Body regulates peripheral T4-to-T3 conversion providing tissue-specific active hormone as needed;
- Better Cardiovascular Function: Normalizes heart rate cardiac output blood pressure and cholesterol reversing hypothyroid cardiovascular abnormalities;
- Better Body Temperature Regulation: Restores normal thermoregulation eliminating cold intolerance and low body temperature symptoms;
- Better Weight Normalization: Restored metabolic rate helps normalize weight though weight loss from levothyroxine alone typically modest;
- Better Cognitive Function Improvement: Reverses hypothyroid-related brain fog memory problems concentration difficulty and mental slowing;
- Better Congenital Hypothyroidism Outcomes: Immediate replacement prevents intellectual disability enabling normal neurological development;
- Better 70+ Year Established Track Record: One of longest continuously marketed prescription medications with unmatched clinical experience since 1955;
- Better Quality of Life: Effective hypothyroidism management dramatically improves quality of life restoring energy cognition mood and cardiovascular function.
Generic Synthroid (Levothyroxine 25 mcg) Medication guide:
Synthroid (Levothyroxine 25/50/100/125/200mcg) represents the dominant US brand of thyroid hormone replacement therapy and one of the longest continuously marketed prescription medications globally — first commercialized by Flint Laboratories in 1955 and subsequently manufactured through Boots, Knoll, Abbott, and now AbbVie Pharmaceuticals. Synthroid contains bioidentical synthetic levothyroxine sodium (T4) - chemically identical to endogenous thyroid hormone naturally produced by the thyroid gland - providing physiological replacement for hypothyroidism from any cause. As direct sibling to Eltroxin (GSK levothyroxine brand from UK/India) on rxshop.md, Synthroid provides the same generic active ingredient but with distinct manufacturer heritage and importantly five available dose strengths (25, 50, 100, 125, 200 mcg) enabling precise individualized dosing without tablet splitting for elderly starting doses, standard adult maintenance, and higher-dose cancer suppression protocols. This comprehensive medication guide covers every aspect of Synthroid therapy from historical significance and AbbVie manufacturing heritage through five-strength dosing precision, bioidentical T4 pharmacology, TSH monitoring framework, comparison with Eltroxin sibling, absorption considerations, special populations including pregnancy elderly and cancer patients, and lifelong therapy management.
💊 Introduction to Synthroid
Synthroid is a prescription oral medication containing levothyroxine sodium as its active ingredient in tablet form. Synthroid was originally commercialized by Flint Laboratories in 1955 as one of the first synthetic thyroid hormone replacement medications and has remained continuously marketed for over 70 years — making it one of the longest continuously marketed prescription medications in modern pharmaceutical history. Through successive corporate ownership (Flint Laboratories → Boots Pharmaceuticals → Knoll Pharmaceuticals → Abbott Laboratories → AbbVie), the Synthroid brand has maintained its position as the dominant United States brand of levothyroxine therapy with historically approximately 90 percent market share in the US thyroid replacement market.
The Synthroid brand available on rxshop.md is manufactured under the historical Abbott/AbbVie heritage — Abbott Laboratories acquired Synthroid in 2001, then divested the specialty pharmaceutical business to AbbVie in 2013 when AbbVie spun off from Abbott. Currently AbbVie Pharmaceuticals owns and manufactures the Synthroid brand. Available in five dose strengths — 25 mcg, 50 mcg, 100 mcg, 125 mcg, and 200 mcg — this multi-strength availability represents a distinctive clinical advantage over single-strength alternatives, enabling precise individualized dosing without requiring tablet splitting for the wide range of clinical situations from elderly cardiac disease starting doses through cancer TSH suppression higher doses.
Synthroid occupies a unique clinical position as direct levothyroxine sibling to Eltroxin (Combitic Global + GSK Pharma India brand) on rxshop.md — both containing identical levothyroxine sodium active ingredient with equivalent therapeutic outcomes expected from bioequivalent generic and brand formulations. The choice between Synthroid and Eltroxin typically depends on patient preference, insurance considerations, prior brand experience, and availability of appropriate dose strengths. Synthroid also serves as opposite indication sibling to Carbirose (carbimazole antithyroid) — while Synthroid replaces deficient thyroid hormone in hypothyroidism, Carbirose blocks excess thyroid hormone production in hyperthyroidism.
🏭 AbbVie/Abbott Manufacturing Heritage
Synthroid Historical Ownership Timeline
Synthroid corporate heritage:
- 1955: Original commercialization by Flint Laboratories - first synthetic T4
- Early years: Established as standard thyroid replacement in US market
- Boots Pharmaceuticals: British pharmaceutical company acquired Synthroid
- Knoll Pharmaceuticals: Continued Synthroid production and expansion
- 2001: Abbott Laboratories acquired Knoll including Synthroid brand
- 2013: Abbott divested specialty pharmaceutical business to AbbVie spinoff
- Present: AbbVie Pharmaceuticals owns and manufactures Synthroid brand
- Market dominance: Historically ~90 percent US levothyroxine market share
- Continuous manufacturing: Over 70 years uninterrupted production
Bioequivalence and Manufacturing Quality
Modern Synthroid is manufactured under strict FDA quality standards with bioequivalent generic alternatives also available. The multi-strength availability (25 through 200 mcg) reflects manufacturing sophistication enabling precise dosage forms. Bioequivalence studies compare pharmacokinetic parameters including area-under-curve (AUC) and peak concentration (Cmax) ensuring generic products meet regulatory standards for equivalence to originator brand products.
⚖️ Synthroid vs Eltroxin Sibling Comparison
| Property | Synthroid | Eltroxin |
|---|---|---|
| Manufacturer | Abbott/AbbVie | Combitic Global + GSK Pharma India |
| Original developer | Flint Labs 1955 | Glaxo/GSK |
| Geographic dominance | US market (~90% share) | UK/India/Canada/Australia |
| Strengths on rxshop | 25, 50, 100, 125, 200 mcg (5 strengths) | 50 mcg (1 strength) |
| Active ingredient | Levothyroxine sodium | Levothyroxine sodium (identical) |
| Mechanism | Bioidentical T4 prohormone | Bioidentical T4 prohormone (identical) |
| Clinical uses | Hypothyroidism replacement | Hypothyroidism replacement (identical) |
| Precision dosing advantage | Multiple strengths - no tablet splitting | May require tablet splitting |
| Historical continuity | Over 70 years continuous | Established international brand |
| Clinical outcomes | Equivalent to Eltroxin | Equivalent to Synthroid |
📏 Five Dose Strengths - Precision Dosing Advantage
Five available Synthroid strengths on rxshop.md:
- 25 mcg: Starting dose elderly/cardiac disease patients, small weight patients, gradual titration
- 50 mcg: Sensitive patient starting dose, small maintenance dose, gradual increases
- 100 mcg: Common adult maintenance dose, standard replacement
- 125 mcg: Intermediate maintenance dose, precise dose adjustments
- 200 mcg: Higher weight patients, cancer TSH suppression protocols
Dose Combinations for Precise Individualization
The five-strength availability enables precise individualization across the full clinical dosing range without requiring tablet splitting:
| Daily Dose | Tablet Combination | Typical Patient |
|---|---|---|
| 25 mcg | 1 x 25 mcg | Elderly starting, cardiac disease |
| 50 mcg | 1 x 50 mcg or 2 x 25 mcg | Sensitive patients, small adults |
| 75 mcg | 1 x 50 mcg + 1 x 25 mcg | Intermediate dose |
| 100 mcg | 1 x 100 mcg | Common adult maintenance |
| 125 mcg | 1 x 125 mcg | Intermediate maintenance |
| 150 mcg | 1 x 100 mcg + 1 x 50 mcg | Higher maintenance |
| 175 mcg | 1 x 125 mcg + 1 x 50 mcg | Higher weight patients |
| 200 mcg | 1 x 200 mcg | Heavy patients, cancer suppression |
| 225 mcg | 1 x 200 mcg + 1 x 25 mcg | Cancer suppression higher |
🧪 Chemistry and Mechanism
Levothyroxine sodium has the chemical formula C15H10I4NNaO4 with molecular weight approximately 798.9 g/mol. Levothyroxine is the sodium salt of the levorotatory isomer of thyroxine — synthetic form chemically identical to endogenous thyroxine (T4) naturally produced by the thyroid gland.
Mechanism as Bioidentical T4 Prohormone
Levothyroxine mechanism at cellular level:
- Absorption: Absorbed primarily in jejunum and ileum with variable bioavailability (60-80 percent)
- Circulation: Bound to thyroxine-binding globulin (TBG) and other proteins (99.97 percent bound)
- Cellular uptake: Free T4 enters target cells through specific transporters
- Peripheral conversion: 5-prime deiodinase enzymes convert T4 to active T3 in tissues
- Nuclear receptor binding: T3 binds thyroid hormone receptors (TR alpha, TR beta) in cell nuclei
- Gene transcription: Receptor complexes modulate transcription of hundreds of thyroid-responsive genes
- Physiological effects: Increased metabolic rate, protein synthesis, gene expression, growth
- Homeostatic feedback: Elevated T4/T3 suppresses hypothalamic TRH and pituitary TSH
Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral bioavailability | 60-80 percent (variable) | Affected by food and medications |
| Time to peak | 2-4 hours | Peak plasma concentration |
| Half-life | Approximately 7 days | Allows once daily dosing |
| Steady state | 4-6 weeks | TSH monitoring at 6-8 weeks |
| Protein binding | 99.97 percent (mostly TBG) | Very highly protein bound |
| Metabolism | Peripheral deiodination to T3 | Body regulates T3 production |
| Elimination | Biliary excretion enterohepatic | Slow elimination |
| Food effect | Substantially reduces absorption | MUST take on empty stomach |
| Onset of clinical improvement | 2-4 weeks partial, 6-8 weeks substantial | Gradual response over weeks |
🎯 Approved Indications
Primary Indications
- Primary hypothyroidism - thyroid gland failure from any cause
- Secondary/tertiary hypothyroidism - pituitary or hypothalamic causes
- Congenital hypothyroidism - newborn screening positive infants
- Nodular goiter management - selected cases with TSH suppression
- Prevention of nodular goiter recurrence after surgical treatment
- Thyroid cancer TSH suppression - after differentiated thyroid cancer treatment
Broader Clinical Uses
- Hashimoto's thyroiditis - autoimmune chronic thyroiditis
- Post-thyroidectomy replacement - after surgical thyroid removal
- Post-RAI ablation - after radioactive iodine treatment
- Central hypothyroidism - pituitary or hypothalamic disease
- Subclinical hypothyroidism - elevated TSH with normal T4 in selected patients
- Myxedema coma - life-threatening severe hypothyroidism (emergency)
- Hypothyroidism in pregnancy - critical for fetal development
- Post-Graves' disease treatment - when patient becomes hypothyroid
- Diffuse euthyroid goiter - selected cases
- TSH suppression test - diagnostic use
- Elderly hypothyroidism - age-related thyroid dysfunction
- Pediatric hypothyroidism - childhood thyroid disorders
Ideal Patient Selection
Synthroid particularly appropriate for:
- Patients preferring US brand-recognition thyroid replacement
- Patients requiring precise dosing not achievable with single strength
- Elderly/CAD patients needing 25 mcg starting dose
- Cancer patients requiring 200 mcg for TSH suppression
- Patients on complex dose combinations avoiding tablet splitting
- Post-thyroidectomy patients requiring standard maintenance
- Congenital hypothyroidism infants requiring immediate replacement
- Pregnant women needing precise dose adjustments
- Patients able to comply with morning empty-stomach dosing
- Patients accepting lifelong therapy commitment
🚫 Contraindications and Precautions
Contraindications
- Untreated thyrotoxicosis - would worsen hyperthyroidism
- Untreated adrenal insufficiency - risk of adrenal crisis - treat cortisol first
- Acute myocardial infarction - initiate cautiously after acute event
- Hypersensitivity to levothyroxine or any excipient
- Not for weight loss - dangerous when used inappropriately in euthyroid patients
Precautions - Cardiovascular Caution
Cardiovascular considerations - critical:
- Elderly patients: Start LOW at 25 mcg, titrate slowly
- Coronary artery disease: Excess thyroid can trigger angina, MI, arrhythmia
- Atrial fibrillation: May be precipitated by overtreatment
- Long-standing untreated hypothyroidism: Start with 25 mcg strength
- Osteoporosis: Overtreatment increases bone loss in postmenopausal women
- Diabetes: Thyroid replacement may affect glucose control
Additional precautions:
- Adrenal insufficiency: Replace glucocorticoids BEFORE thyroid hormone
- Pregnancy: Requirements increase 20-30% - monitor monthly
- Anticoagulation: Thyroid replacement affects warfarin sensitivity
- Diabetes medications: May need adjustment as thyroid normalizes
- Estrogen therapy: May increase levothyroxine requirements
💉 Dosage and Administration
Standard Adult Dosing
Standard Synthroid adult dosing:
- Weight-based: Approximately 1.6 mcg/kg/day for full replacement
- Typical adult dose: 100-150 mcg once daily
- Range: 25-200 mcg (five strengths cover full range)
- Once daily dosing: Long half-life supports single daily dose
- Timing: Empty stomach 30-60 minutes before breakfast
Weight-Based Strength Selection
| Weight | Full Replacement (1.6 mcg/kg) | Synthroid Strength Combination |
|---|---|---|
| 50 kg | 80 mcg | 1 x 50 + 1 x 25 mcg (75 mcg) or 1 x 100 mcg |
| 60 kg | 96 mcg | 1 x 100 mcg |
| 70 kg | 112 mcg | 1 x 100 + 1 x 25 mcg (125 mcg tablet) |
| 80 kg | 128 mcg | 1 x 125 mcg |
| 90 kg | 144 mcg | 1 x 100 + 1 x 50 mcg (150 mcg) |
| 100 kg | 160 mcg | 1 x 125 + 1 x 25 mcg or 1 x 200 mcg maintenance |
Elderly and CAD Approach with 25 mcg
Synthroid 25 mcg advantage for elderly/CAD:
- Starting dose: 25 mcg once daily (no tablet splitting needed)
- Titration: Increase by 25 mcg every 6-8 weeks based on TSH
- Progression: 25 → 50 → 75 → 100 mcg typical path
- Target: Achieve euthyroid state slowly to prevent cardiac stress
- Monitor for: Chest pain, palpitations, arrhythmias, worsening heart failure
- Cardiac evaluation: Consider before starting in patients with significant CAD
Pregnancy Dosing Adjustments
Pregnancy adjustments:
- Requirements increase 20-30 percent during pregnancy
- Increase dose immediately upon pregnancy confirmation
- Typical approach: Add appropriate Synthroid strength to reach higher dose
- Example: 100 mcg pre-pregnancy → 125 mcg during pregnancy
- Monitor TSH monthly throughout pregnancy
- Target TSH: First trimester 0.1-2.5, second 0.2-3.0, third 0.3-3.5
- Return to pre-pregnancy dose after delivery
- Critical for fetal brain development particularly first trimester
Cancer TSH Suppression with 200 mcg
Synthroid 200 mcg advantage for cancer patients:
- Higher than replacement doses: Typically 2.0-2.4 mcg/kg/day
- Target TSH: Below 0.1 mIU/L for high-risk thyroid cancer
- Intermediate suppression: 0.1-0.5 mIU/L for intermediate-risk
- 200 mcg strength enables: Single tablet doses 200-300 mcg range
- Additional strengths: Combine with 25 mcg for precise 225 mcg or 250 mcg
- Requires close monitoring: Balance suppression vs cardiovascular/bone effects
🍴 Critical Absorption Considerations
Levothyroxine absorption critically affected by food and medications:
Optimal administration:
- Take on EMPTY STOMACH with water only
- 30-60 minutes before breakfast is optimal timing
- Alternative: Bedtime - at least 3 hours after last meal
- Consistency: Same time daily for stable levels
- Water only: No coffee, tea, juice with the dose
- Do not chew or crush - swallow whole with water
Foods and Medications Affecting Absorption
Wait at least 4 hours before/after:
- Coffee and caffeine: Reduces absorption 30-40 percent
- Calcium supplements: Binds levothyroxine reducing absorption
- Iron supplements: Forms complexes reducing absorption
- Magnesium supplements: Interferes with absorption
- Aluminum antacids: Reduces absorption
- Sucralfate: Binds levothyroxine
- Cholestyramine and other bile acid sequestrants: Substantial binding
- Proton pump inhibitors: Reduces absorption
- Milk and dairy: Calcium content reduces absorption
- Soy protein and fiber: May reduce absorption
- Estrogen therapy: Increases TBG, may increase requirements
📊 TSH Monitoring Framework
TSH monitoring schedule:
- Initial dose: Check TSH at 6-8 weeks after starting
- Dose changes: Check TSH at 6-8 weeks after each adjustment
- Once stable: Annual TSH monitoring
- Pregnancy: Monthly TSH monitoring
- Elderly: Every 6 months minimum
- Cancer suppression: Every 3-6 months
- Symptom change: Repeat TSH sooner if symptoms worsen
Target TSH Ranges
| Population/Indication | Target TSH (mIU/L) |
|---|---|
| Standard adult replacement | 0.5-4.0 |
| Elderly patients | 1.0-5.0 (higher acceptable) |
| Pregnancy first trimester | 0.1-2.5 |
| Pregnancy second trimester | 0.2-3.0 |
| Pregnancy third trimester | 0.3-3.5 |
| Thyroid cancer high-risk suppression | Below 0.1 |
| Thyroid cancer intermediate-risk | 0.1-0.5 |
| Pediatric replacement | 0.5-4.0 |
⚠️ Side Effects
Signs of Overtreatment
Overtreatment symptoms (dose too high):
- Palpitations, tachycardia
- Weight loss despite normal appetite
- Heat intolerance, excessive sweating
- Anxiety, nervousness, irritability
- Insomnia, sleep disturbance
- Tremor
- Diarrhea, increased bowel movements
- Muscle weakness
- Atrial fibrillation (elderly particularly)
- Bone loss (postmenopausal women)
Signs of Undertreatment
Undertreatment symptoms (dose too low):
- Persistent fatigue
- Cold intolerance continues
- Weight gain difficulty losing
- Constipation
- Dry skin and hair
- Continued depression, low mood
- Cognitive slowing continues
- Muscle aches
- Elevated cholesterol
🔄 Drug Interactions
| Drug/Substance | Interaction |
|---|---|
| Warfarin | Increased anticoagulant effect - monitor INR |
| Diabetes medications | Thyroid normalization may reduce needs |
| Calcium supplements | Reduces absorption - separate by 4 hours |
| Iron supplements | Reduces absorption - separate by 4 hours |
| Cholestyramine | Substantial binding - separate by 4-6 hours |
| PPIs (omeprazole) | Long-term use may reduce absorption |
| Estrogen therapy | Increases TBG - may need dose increase |
| Amiodarone | Complex thyroid effects - monitor closely |
| Coffee and caffeine | Reduces absorption 30-40% |
| Lithium | Can cause hypothyroidism |
🛡️ Special Populations
- Pregnancy
- Requirements increase 20-30 percent. Increase dose immediately. Five available strengths enable precise pregnancy dose adjustments without splitting. Monitor TSH monthly. Return to pre-pregnancy dose after delivery.
- Lactation
- Compatible with breastfeeding. Minimal breast milk excretion. Continue normal replacement during nursing.
- Pediatric Patients
- Critical for growth and neurological development. Weight-based dosing higher per kg than adults. 25 mcg and 50 mcg strengths enable precise pediatric doses. Pediatric endocrinology supervision essential.
- Elderly Patients Over 65
- Start LOW with Synthroid 25 mcg. Titrate every 6-8 weeks. Higher TSH targets acceptable. Careful cardiovascular monitoring. Consider ECG baseline in cardiac disease.
- Coronary Artery Disease
- Start very low (25 mcg), titrate very slowly. 25 mcg strength particularly valuable. Consider cardiac evaluation before starting. Beta-blocker may be needed during titration.
- Adrenal Insufficiency
- Treat adrenal insufficiency BEFORE thyroid hormone. Levothyroxine before glucocorticoid replacement can precipitate adrenal crisis.
- Post-Thyroidectomy Patients
- Essential lifelong replacement. Full replacement dose based on weight (1.6 mcg/kg/day). Multiple strengths enable precise dose achievement.
- Thyroid Cancer Patients
- 200 mcg strength particularly useful for suppression protocols. Target TSH varies by cancer risk. Combine strengths for precise higher doses. Endocrinology supervision essential.
- Diabetic Patients
- Thyroid normalization may reduce insulin needs. Monitor blood glucose closely during titration.
- Osteoporosis Patients
- Avoid overtreatment - excess thyroid increases bone loss. Target upper end of normal TSH range. Regular DEXA monitoring.
- Congenital Hypothyroidism Infants
- Critical to start immediately after positive newborn screening. Initial dose 10-15 mcg/kg/day. 25 mcg tablets enable precise infant dosing. Regular pediatric endocrinology follow-up.
- Weight Change Patients
- Significant weight change (over 10 percent) may require dose adjustment. Multiple strengths enable precise adjustment. Reassess TSH after weight change.
📆 Long-Term Follow-Up
Lifelong therapy considerations:
- Annual TSH monitoring: Once stable dose established
- Symptom assessment: At each visit
- Weight monitoring: Track for dose adjustment need
- Cardiovascular monitoring: Particularly in elderly
- Bone density monitoring: Postmenopausal women periodic DEXA
- Pregnancy planning: Optimize TSH before conception
- Medication changes: Reassess for new interactions
- Brand consistency: Try to maintain same brand for consistent absorption
- Life changes: Weight changes over 10% may require adjustment
📦 Storage and Handling
- Store at room temperature between 20°C and 25°C (68°F and 77°F)
- Protect from light, moisture, and heat
- Keep tablets in original packaging
- Keep out of reach of children and pets
- Do not use past expiration date
- Do not share medication with others
- Maintain consistent supply - avoid missing doses
- Different strengths have different tablet colors - verify strength before taking
👨⚕️ When to Contact Your Doctor
- Signs of overtreatment: palpitations, weight loss, heat intolerance
- Signs of undertreatment: persistent fatigue, cold intolerance, weight gain
- Chest pain or worsening angina
- Atrial fibrillation or new arrhythmia
- Confirmed or suspected pregnancy - dose increase needed
- Starting or stopping medications potentially interacting
- Starting calcium, iron, PPI, or estrogen therapy
- Significant weight change (over 10 percent)
- Development of new medical conditions
- Time for scheduled TSH monitoring
- Symptoms not improving after 6-8 weeks of therapy
- Signs of allergic reaction
- Difficulty tolerating the medication
- Missing doses regularly
- Considering brand or strength change
🌟 Key Takeaways
Essential points about Synthroid therapy:
- Synthroid is Abbott/AbbVie brand levothyroxine sodium in 5 strengths (25/50/100/125/200 mcg)
- One of longest continuously marketed prescription medications (Flint Labs 1955)
- Dominant US brand with historically ~90% market share in US levothyroxine
- Direct sibling to Eltroxin (GSK levothyroxine) - identical generic
- Opposite indication sibling to Carbirose (carbimazole antithyroid)
- Bioidentical synthetic T4 - chemically identical to endogenous thyroid hormone
- Prohormone peripherally converted to active T3 by tissue enzymes
- Five dose strengths enable precise individualized dosing without tablet splitting
- 25 mcg starting dose ideal for elderly and CAD patients
- 200 mcg strength particularly useful for cancer TSH suppression
- Long ~7-day half-life allows once daily dosing
- Steady state 4-6 weeks - clinical assessment requires patience
- Adult replacement 1.6 mcg/kg/day average (typically 100-150 mcg)
- Elderly/CAD: start 25 mcg, titrate slowly
- Pregnancy: increase 20-30% requirements, monitor monthly
- Take on EMPTY STOMACH 30-60 min before breakfast
- Wait 4 hours before/after coffee calcium iron cholestyramine
- Monitor TSH q6-8 weeks during titration, annually once stable
- Target TSH 0.5-4.0 for standard replacement
- Treat adrenal insufficiency BEFORE starting levothyroxine
- Lifelong therapy typical for most causes
Important Medical Disclaimer: This medication guide provides general information about Synthroid (Abbott/AbbVie levothyroxine tablets in 5 strengths 25/50/100/125/200 mcg) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by a qualified healthcare provider before starting continuing or discontinuing thyroid hormone replacement therapy. Levothyroxine therapy requires regular TSH monitoring and dose adjustments - do not modify dose without physician guidance. The five available strengths enable precise dosing but require careful strength verification before taking each dose. Take on empty stomach 30-60 minutes before breakfast with water only. Avoid coffee calcium iron cholestyramine and other interfering substances within 4 hours. Elderly patients and those with coronary artery disease require careful low-dose initiation with slow titration - Synthroid 25 mcg is ideal starting strength for these populations. During pregnancy requirements increase 20-30 percent - inform your obstetrician immediately if pregnant so dose can be increased and monitoring intensified. TSH monitoring critical: every 6-8 weeks during titration annually once stable monthly during pregnancy. Treat adrenal insufficiency BEFORE starting levothyroxine to prevent adrenal crisis. Report signs of overtreatment (palpitations weight loss heat intolerance) or undertreatment (persistent fatigue cold intolerance) to your healthcare provider. Do not use for weight loss in non-hypothyroid patients - dangerous inappropriate use. Levothyroxine typically requires lifelong therapy for most hypothyroid causes. If you experience concerning symptoms particularly chest pain new arrhythmias or difficulty tolerating the medication contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance from your endocrinologist or primary care physician.
Synthroid — Frequently Asked Questions
-
What is Synthroid used for?
Synthroid is used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. It's also used for the treatment of goiter and thyroid cancer. -
How does Synthroid work?
Synthroid replaces or provides more thyroid hormone, which is normally produced by the thyroid gland, helping to normalize body metabolism. -
How should I take Synthroid?
Take Synthroid once daily on an empty stomach, 30 to 60 minutes before breakfast, with a full glass of water. Consistency in timing maximizes absorption. -
What happens if I miss a dose of Synthroid?
If you miss a dose, take it as soon as you remember, but if it's close to the time of your next dose, skip the missed dose. Never double up doses. -
Can Synthroid be taken during pregnancy?
Yes, it's crucial to continue taking Synthroid during pregnancy as thyroid hormone levels are important for fetal development. Dosage adjustments may be necessary. -
Are there any foods or supplements I should avoid while taking Synthroid?
Yes, avoid consuming high-fiber foods, soy products, cottonseed meal, walnuts, and dietary supplements like calcium and iron within 4 hours of taking Synthroid. -
How long does it take for Synthroid to start working?
While some symptoms may improve within a few weeks, it can take several months to see the full benefits of Synthroid.
See all Synthroid questions (32)
More Thyroid Medications
